Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex

Infectious Diseases

Volumn 47, Issue 6, 2015, Pages 370-378

  Lin, Huang Shen ^a   Lee, Ming Hsun ^b   Cheng, Chun Wen ^b   Hsu, Po Chang ^b   Leu, Hsieh Shong ^b   Huang, Ching Tai ^b   Ye, Jung Jr ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Acinetobacter calcoaceticus Acinetobacter baumannii complex; Multidrug resistant; Pneumonia; Sulbactam

Indexed keywords

SULBACTAM; SULTAMICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER CALCOACETICUS-BAUMANNII COMPLEX; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTION; ADULT; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PNEUMONIA, BACTERIAL; TAIWAN; TIME;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTIONS; ADULT; AGED; AMPICILLIN; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; SULBACTAM; TAIWAN; TIME FACTORS;

EID: 84957410820     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365548.2014.995129     Document Type: Article

References (27)

1. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, et al Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan Emerg Infect Dis 2002; 8: 827-32.
2. Playford E G, Craig J C, Iredell J R.Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences J Hosp Infect 2007; 65: 204-11.
3. Sunenshine RH, W right MO, Maragakis LL, Harris A D, Song X, Hebden J, et al Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization Emerg Infect Dis 2007; 13: 97-103.
4. Ye JJ, Huang CT, Shie SS, Huang PY, Su LH, Chiu CH, e t al Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains PLoS One 2010; 5(4): e9947.
5. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G.High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii Scand J Infect Dis 2007; 39: 38-43.
6. Wood G C, Hanes S D, Croce M A, Fabian T C, Boucher BA Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-Associated pneumonia Clin Infect Dis 2002; 34: 1425-30.
7. Levin A S, Levy CE, Manrique A E, Medeiros EA, Costa SF Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam Int J Antimicrob Agents 2003; 21: 58-62.
8. Curcio D, Fern án dez F, Vergara J, Vazquez W, Luna C M.Late onset ventilator-Associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline J Chemother 2009; 21: 58-62.
9. Ye J J, Lin H S, Kuo AJ, Leu H S, Chiang P C, Huang C T, et al The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii J Infect 2011; 63: 351-61.
10. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almod ó var AE, Garc í a-Garmendia JL, Bernabeu-Wittell M, et al Treatment of multidrug-resistant Acinetobacter baumannii ventilator-Associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP Clin Infect Dis 2003; 36: 1111-8.
11. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Soro M, et al Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii J Antimicrob Chemother 1998; 42: 793-802.
12. Brauers J, Frank U, Kresken M, Rodloff AC, Seifert H.Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains Clin Microbiol Infect 2005; 11: 24-30.
13. Higgins PG, W isplinghoff H, Stefanik D, Seifert H.In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains Antimicrob Agents Chemother 2004; 48: 1586-92.
14. Ko W C, Lee H C, Chiang S R, Yan J J, W u J J, Lu CL, e t al In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain J Antimicrob Chemother 2004; 53: 393-5.
15. Kiffer CR, Sampaio JL, Sinto S, Oplustil CP, Koga PC, Arruda AC, et al In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii Diagn Microbiol Infect Dis 2005; 52: 317-22.
16. Sader HS, Jones RN Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp Int J Antimicrob Agents 2005; 25: 380-4.
17. [17]Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, et al Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study Pharmacotherapy 2007; 27: 1506-11.
18. Schreckenberger P C, Daneshvar M I, W eyant R S, Hollis DG A cinetobacter, Achromobacter, Chryseobacterium, Moraxella and other nonformentative gram-negative rods In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Louise-Landry M, Warnock DW, editors Manual of clinical microbiology 10th ed Washington, DC: American Society of Microbiology; 2011 p 714-38.
19. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-Acquired, ventilator-Associated, and healthcare-Associated pneumonia Am J Respir Crit Care Med 2005; 171: 388-416.
20. Fujitani S, Cohen-Melamed MH, Tuttle RP, Delgado E, Taira Y, Darby JM Comparison of semi-quantitative endotracheal aspirates to quantitative non-bronchoscopic bronchoalveolar lavage in diagnosing ventilator-Associated pneumonia Respir Care 2009; 54: 1446-8.
21. Man S Y, Chan K M, W ong F Y, W ong K Y, Yim C L, Mak P S, et al Evaluation of the performance of a modified acute physiology and chronic health evaluation (APACHE II) scoring system for critically ill patients in emergency departments in Hong Kong Resuscitation 2007; 74: 259-65.
22. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing, twenty-first informational supplement CLSI document M100-S21 Wayne, PA: CLSI; 2011.
23. Paterson DL The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species Clin Infect Dis 2006; 43: 43-8.
24. Sheng W H, W ang J T, Li S Y, Lin YC, Cheng A, Chen YC, et al Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU Diagn Microbiol Infect Dis 2011; 70: 380-6.
25. Wadl M, Heckenbach K, Noll I, Ziesing S, Pfister W, Beer J, et al Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolated from four German university hospitals Infection 2010; 38: 47-51.
26. Lee SC, Huang SS, See LC, Tsai MH, Shieh WB In vitro activities of nine current antibiotics against culprit bacteria in nosocomial infections in an institution in northern Taiwan Chang Gung Meg J 2011; 34: 580-9.
27. Lee YC, Huang Y T, Tan CK, Kuo YW, Liao CH, Lee PI, et al Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes J Antimicrob Chemother 2011; 66: 1839-46.